Home › Singulex to Seek FDA Clearance for Sgx Clarity; Aims for Point-of-Care Prototype by Year End

Singulex to Seek FDA Clearance for Sgx Clarity; Aims for Point-of-Care Prototype by Year End

Jan 20, 2017
|
Monica Heger
Premium

NEW YORK (GenomeWeb) – Singulex plans to list its single-molecule counting Sgx Clarity instrument as a CE-marked in vitro diagnostic in Europe at the end of March and plans to submit it for US Food and Drug Administration clearance in the second half of the year, according to Singulex CEO Guido Baechler.

In an interview at the recent JP Morgan Healthcare conference in San Francisco, Baechler provided an update on the firm's activities in the immunodiagnostics space and in developing its single-molecule counting (SMC) technology for various applications.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS Approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

What's Popular?

In Molecular Diagnostics

  1. Liquid Biopsy Panel Expansion Enables Admera Health to Add Immunotherapy Prediction

    Premium

  2. Labs, Advocacy Groups Push Back on Medicare Policy Shift on NGS Testing for Hereditary Cancer Risk

    Premium

  3. Medicare Covers Adaptive Biotechnologies' ClonoSeq Assay

  4. Curetis Subsidiary Ares Ramping Up NGS Antibiotic Resistance Testing Business

    Premium

  5. BioFluidica Applying Liquid Biopsy to Detect Leukemia While Reducing Biopsies

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.